Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
Miyazaki et al – 2011 (view as PDF)...
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
News & Articles
Risk of anaphylaxis after vaccination in children and adults
McNeil et al – 2016 (view as PDF)...
Survivin as a novel target protein for reducing the proliferation of cancer cells (Review)
Li, Hu and Li -2018 (view as PDF)...
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter et al – 2009 (view as PDF)...
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
Johnson et al -2001 (view as PDF)...
Expression and clinical significance of survivin in ovarian cancer: A meta-analysis
He et al – 2018 (view as PDF)...
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English